Using xanthohumol to reduce symptoms of viral infections

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate whether regular oral supplementation of xanthohumol can lessen the severity and duration of symptoms associated with viral infections. Participants will be enrolled in a placebo-controlled trial where they will receive either xanthohumol or a placebo twice daily for 90 days. Blood samples will be collected at the start of the study, and again at 45 and 90 days, to monitor any changes. If participants develop a respiratory infection during the study, they will be asked to perform a self-test to assess their condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* healthy
* BMI \>18 kg/m² or \< 28kg/m²

Exclusion Criteria:

* food intolerances
* food allergies
* chronic inflammatory diseases
* metabolic diseases
* viral or bacterial infections within the last 3 weeks of inclusion
* intake of immunosuppressive medication
* severe acute respiratory syndrome coronavirus type 2-infection in the last 4 months
* influenza infection in the "current" flu season

Where it's running

• University of Vienna
  Vienna, Austria Recruiting

Study contacts

• Study coordinator: Ina Bergheim, Prof. Dr.
• Email: ina.bergheim@univie.ac.at
• Phone: +43-1-4277-54981

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood-based metagenomic sequencing to find infections in immunocompromised adults

  We will test whether adding the Karius Spectrum blood test to usual diagnostic care helps doctors find and treat infections faster in immunocompromised adults evaluated as outpatients.

  Recruiting at 4 sites Karius, Inc. · San Francisco, California and 5 other locations · NCT07110636

• Identifying biomarkers for diagnosing sepsis in the emergency room

  This study is trying to find out if certain immune responses can help doctors spot sepsis in patients with infections when they arrive at the emergency room.

  Recruiting at 2 sites Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Almere Stad, Flevoland and 2 other locations · NCT06178822

• Biomarkers linked to congenital CMV using newborn blood spots

  Researchers will test protein and RNA markers in dried blood spots from newborns to see if they can identify congenital CMV sequelae early.

  Recruiting at 2 sites Copenhagen University Hospital, Rigshospitalet · Copenhagen and 1 other locations · NCT07635368

• Investigating how cold viruses affect bronchiectasis exacerbations

  This study is trying to see if cold viruses make symptoms worse for people with bronchiectasis compared to healthy individuals.

  Recruiting Imperial College London · London · NCT06931002

• Controlled exposure to a viral mimic for studying lung immune responses

  This study tests how people with asthma and healthy volunteers respond to a safe viral mimic to help understand and improve treatments for lung inflammation and asthma.

  Recruiting Cambridge University Hospitals NHS Foundation Trust · Cambridge, Cambridgeshire · NCT06488118

• HEPA air cleaners in inner-city elementary school classrooms

  This trial will test whether placing HEPA air cleaners in elementary classrooms lowers airborne virus levels and reduces infections among students, teachers, and household members.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT05953233

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.